Alessandro Morabito
Oncology — Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Italy
Alessandro Morabito
LeadR Profile
Oncology
Subspecialties: Pulmonology - Biochemistry - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2004 - 2026
Number : 397
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer. cells, lung, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma | J Clin Oncol Top journal | 2026 | 2 |
| MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells. cells, lung, gefitinib, micrornas, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, cell line, small cell lung carcinoma, therapeutics, mutation | Cells | 2026 | 0 |
| Response to Letter Re: Real-world outcomes of immunotherapy discontinuation at two years in advanced non-small cell lung cancer: Final results of the ISTOP study. cells, lung, neoplasms, carcinoma, non-small-cell lung, immunotherapy, lung neoplasms, small cell lung carcinoma | Eur J Cancer | 2026 | 0 |
| Imaging and AI in tertiary prevention of lung cancer: Narrative review and clinical perspectives. lung, neoplasms, lung neoplasms, deep learning, therapeutics, learning, artificial intelligence, tertiary prevention | Multidiscip Respir Med | 2026 | 0 |
| Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD. lung, safety, pharmaceutical preparations, neoplasms, carcinoma, non-small-cell lung, drug tapering, therapeutics | Ann Oncol Top journal | 2026 | 0 |
Clinical Studies 54
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
5 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases 2023-507494-18-00 — oncogenes, proto-oncogenes, cells, genes, lung, receptor protein-tyrosine kinases, safety, neoplasms, gene rearrangement, carcinoma, non-small-cell lung, central nervous system, lung neoplasms, neoplasm metastasis, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, nervous system, crizotinib | Phase 3 | Active not recruiting | 2021 |
| Beamion LUNG 3 A study to test whether zongertinib helps people with surgically removed non small cell lung cancer with HER2 mutations compared with standard treatment 2025-521284-12-00 — cells, lung, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, mutation, her2 mutation | Phase 3 | Not yet recruiting | 2026 |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated KRAS G12C Mutated Advanced or Metastatic Non Squamous Non Small Cell Lung Cancer 2024-518365-10-00 — cells, pemetrexed, lung, safety, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, carboplatin | Phase 3 | Recruiting | 2025 |
| A Study of Dato DXd in Combination With Durvalumab and Carboplatin for First line Treatment of Advanced NSCLC Without Actionable Genomic Alterations 2023-505993-14-00 — cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, biomarkers, lung neoplasms, small cell lung carcinoma, therapeutics, carboplatin, chemotherapy | Phase 3 | Active not recruiting | 2023 |
| BEAMION Lung 2 A study to test whether zongertinib (BI 1810631) helps people with advanced non small cell lung cancer with HER2 mutations compared with standard treatment 2023-504308-27-00 — cells, lung, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, lung neoplasms, small cell lung carcinoma, protein-tyrosine kinases, tyrosine, therapeutics, mutation, her2 mutation | Phase 3 | Active not recruiting | 2024 |
LeadR Networks
Main global connection map